This is complex, but I wouldn’t really put Bisantrene into the preclinical stage for FTO - it is really more Phase I. The reason why is we know a huge amount about how Bisantrene behaves in humans that you just don’t know with a typical preclinical drug especially around safety, metabolism and pharmacology. Phase I is all about safety and dosing, what we lack is human data (for FTO) around efficacy (Phase II/III data)
From a FTO risk perspective I would consider Bisantrene to have the same risk profile of a typical drug that had passed Phase I (i.e. safe), but without any efficacy data.
Pillar 1 - FTO (new thread), page-430
-
- There are more pages in this discussion • 2,545 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |